欧盟批准为患有罕见胆固醇紊乱的6个月小儿童提供Evkeeza。 EU approves Evkeeza® for children as young as 6 months with a rare cholesterol disorder.

欧洲联盟委员会已经批准Evkeeza为患有Homezygous Familial Hiperchoterolology(HOFH)的6个月幼童提供Evkeeza,这是一种罕见的遗传疾病,导致胆固醇含量极高。 The European Commission has approved Evkeeza® for children as young as 6 months with Homozygous Familial Hypercholesterolemia (HoFH), a rare genetic disorder causing extremely high cholesterol levels. 这一批准允许提前治疗,有可能降低年轻患者早期心血管疾病的风险。 This approval allows for earlier treatment, potentially reducing the risk of early cardiovascular disease in young patients. Evkeeza是欧盟为这个与HoFH同龄的年龄组批准的第一种药品。 Evkeeza® is the first medicine approved in the EU for this age group with HoFH.